The use of mycophenolate mofetil in experimental encapsulating peritoneal sclerosis

Huddam B., Basaran M., Kocak G., Azak A., Yalcin F., Reyhan N. H., ...More

INTERNATIONAL UROLOGY AND NEPHROLOGY, vol.47, no.8, pp.1423-1428, 2015 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 47 Issue: 8
  • Publication Date: 2015
  • Doi Number: 10.1007/s11255-015-1015-z
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Page Numbers: pp.1423-1428
  • Çanakkale Onsekiz Mart University Affiliated: Yes


Encapsulated peritoneal sclerosis (EPS) is a rare complication of long-term peritoneal dialysis usually associated with the inadequacy and early termination of dialysis modality. Adequate treatment of peritoneal fibrosis has not been achieved by medical intervention so far. Mycophenolate mofetil (MMF), which inhibits inosine monophosphate dehydrogenase reversibly and highly selectively, is the most widely used drug for maintenance immunosupression in renal transplantation. Recent studies have shown that MMF has also antifibrotic effects. In this study, we evaluated the effects of MMF on EPS model in rats based on antifibrotic effects.